<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00632307</url>
  </required_header>
  <id_info>
    <org_study_id>lkhemer1-2008</org_study_id>
    <nct_id>NCT00632307</nct_id>
  </id_info>
  <brief_title>Breath Analysis by Ion Mobility Spectrometry</brief_title>
  <official_title>Detection of Clusters of Volatile Organic Compounds (VOC)in Patients With Different Lung Disorders by Ion Mobility Spectrometry. Different Clusters of VOC in the Diagnosis of Different Lung Disorders Using Ion Mobility Spectrometry</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lung Clinic Hemer</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Lung Clinic Hemer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Recognition of disease specific clusters of volatile organic compounds in patients with
      different lung diseases, using breath analysis with ion mobility spectrometry. Lung diseases
      of interest are:

        -  COPD

        -  tumors

        -  airway infection

        -  interstitial lung disease

        -  sleep apnea Hypothesis: Breath analysis with ion mobility spectrometry can differentiate
           pulmonary disorders.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Recruitment of patients with different lung diseases goes on. First sub-group analysis of
      patients with COPD,lung cancer and sarcoidosis is done in order to create a training set of
      VOC-clusters for further validation in a bigger population of patients.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2006</start_date>
  <completion_date type="Anticipated">June 2023</completion_date>
  <primary_completion_date type="Anticipated">June 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Identification of diseases specific VOCs</measure>
    <time_frame>years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change of disease specific VOCs under therapy</measure>
    <time_frame>years</time_frame>
  </secondary_outcome>
  <number_of_groups>8</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Lung Diseases</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <description>COPD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <description>lung cancer</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <description>airway infection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <description>interstitial lung disease</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5</arm_group_label>
    <description>sleep apnea</description>
  </arm_group>
  <arm_group>
    <arm_group_label>6</arm_group_label>
    <description>pulmonary disorders with pleural infusions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>7</arm_group_label>
    <description>sarcoidosis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>8</arm_group_label>
    <description>healthy persons</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      breath, pleural fluid (only in patients with therapeutic pleurocentesis)
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        patients of the lung clinic hemer with pulmonary diseases.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Any patient

          -  Ages 18-90 years old

        Exclusion criteria:

        - Patient who are not able to perform an exhalation manoever.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Westhoff, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lung Clinic Hemer, 58675 Hemer, Germany</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michael Westhoff, MD</last_name>
    <phone>004923729082203</phone>
    <email>michael.westhoff@lkhemer.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Patric Litterst, MD</last_name>
    <phone>004923729082545</phone>
    <email>pneumologie@lkhemer.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Lung Clinic Hemer</name>
      <address>
        <city>Hemer</city>
        <zip>58675</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Westhoff, MD</last_name>
      <phone>004923729082203</phone>
      <email>michael.westhoff@lkhemer.de</email>
    </contact>
    <contact_backup>
      <last_name>Patric Litterst, MD</last_name>
      <phone>004923739082545</phone>
      <email>pneumologie@lkhemer.de</email>
    </contact_backup>
    <investigator>
      <last_name>Michael Westhoff, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Westhoff, M; Litterst, P; Bödeker, B; Baumbach, J: Beath analysis by IMS for differentiation of COPD und Interstitial Lung Disease Pneumologie; 2011, 65: P278</citation>
  </reference>
  <reference>
    <citation>Westhoff, M; Litterst, P; Madulla S, Bödeker, B; Baumbach, J Differentiation of COPD patients including patients with lung cancer from healthy persons by IMS. Implementation of statistic and bioinformatic methods. Pneumologie 2012; 66: V394</citation>
  </reference>
  <reference>
    <citation>Westhoff M, Litterst P, Maddula S, Baumbach JI Differentiation of chronic obstructive pulmonary disease (COPD) including lung cancer from healthy control group by breath analysis using ion mobility spectrometry Eur Respir J 2011; 38: Suppl 55, P1699</citation>
  </reference>
  <reference>
    <citation>Westhoff M, Litterst P, Sommer H, Bödeker B, Baumbach JI Volatile organic compounds in exhaled breath of patients with COPD ± lung cancer and their correlation with FEV1-values. Eur Respir J 2014; 44: Suppl 58, P987</citation>
  </reference>
  <results_reference>
    <citation>Bunkowski A, Bödeker B, Bader S, Westhoff M, Litterst P, Baumbach JI. MCC/IMS signals in human breath related to sarcoidosis-results of a feasibility study using an automated peak finding procedure. J Breath Res. 2009 Dec;3(4):046001. doi: 10.1088/1752-7155/3/4/046001. Epub 2009 Sep 23.</citation>
    <PMID>21386194</PMID>
  </results_reference>
  <results_reference>
    <citation>Westhoff M, Litterst P, Freitag L, Urfer W, Bader S, Baumbach JI. Ion mobility spectrometry for the detection of volatile organic compounds in exhaled breath of patients with lung cancer: results of a pilot study. Thorax. 2009 Sep;64(9):744-8. doi: 10.1136/thx.2008.099465. Epub 2009 Jan 21.</citation>
    <PMID>19158121</PMID>
  </results_reference>
  <results_reference>
    <citation>Westhoff M, Litterst P, Freitag L, Baumbach JI. Ion mobility spectrometry in the diagnosis of sarcoidosis: results of a feasibility study. J Physiol Pharmacol. 2007 Nov;58 Suppl 5(Pt 2):739-51.</citation>
    <PMID>18204189</PMID>
  </results_reference>
  <results_reference>
    <citation>Bunkowski A, Maddula S, Davies AN, Westhoff M, Litterst P, Bödeker B, Baumbach JI. One-year time series of investigations of analytes within human breath using ion mobility spectrometryInt. J. Ion Mobil. Spec. (2010) 13:141-148</citation>
  </results_reference>
  <results_reference>
    <citation>Westhoff, M, Litterst P, Maddula S, Bödeker B, Rahman S, Davies AN, Baumbach JI. Differentiation of chronic obstructive pulmonary disease (COPD) including lung cancer from healthy control group by breath analysis using ion mobility spectrometry. Int. J. Ion Mobil. Spec. (2010) 13:131-139</citation>
  </results_reference>
  <results_reference>
    <citation>Vautz W. Baumbach JI, Westhoff M, Züchner, K, Carstens ETH, Perl T. Breath sampling control for medical application. Int. J. Ion Mobil. Spec. (2010) 13:41-46</citation>
  </results_reference>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 29, 2008</study_first_submitted>
  <study_first_submitted_qc>March 7, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 10, 2008</study_first_posted>
  <last_update_submitted>March 5, 2018</last_update_submitted>
  <last_update_submitted_qc>March 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Lung Clinic Hemer</investigator_affiliation>
    <investigator_full_name>Michael Westhoff MD</investigator_full_name>
    <investigator_title>Dr. Michael Westhoff</investigator_title>
  </responsible_party>
  <keyword>lung tumor</keyword>
  <keyword>pleural tumor</keyword>
  <keyword>interstitial lung disease</keyword>
  <keyword>airway infection</keyword>
  <keyword>COPD</keyword>
  <keyword>sleep apnea</keyword>
  <keyword>ion mobility spectrometry</keyword>
  <keyword>breath analysis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

